Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,409 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04389229 | OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)(OVSTAR) | withdrawn | Phase 1 / Phase 2 | 0 | Immetacyte LtdINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT02520752 |
| A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors |
| completed |
| Phase 1 |
| 37 |
| Novartis PharmaceuticalsINDUSTRY |
| 7 |
| Dec 10, 2020 |
| clinicaltrials |
| NCT02626234 | A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors | completed | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT00620594 | A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | completed | Phase 1 | 183 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01223898 | To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib | completed | Phase 1 | 19 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 9, 2020 | clinicaltrials |
| NCT01471847 | A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab | completed | Phase 1 | 5 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 9, 2020 | clinicaltrials |
| NCT01634061 | Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | completed | Phase 1 | 43 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT00969046 | Dose-Escalation Study in Advanced Colon Cancer Patients | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT02077933 | Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | completed | Phase 1 | 79 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 8, 2020 | clinicaltrials |
| NCT02757651 | KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response | completed | Phase 1 / Phase 2 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT02581878 | Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma | completed | Phase 1 | 21 | BayerINDUSTRY | 2 | Nov 25, 2020 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03704467 | Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | completed | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Nov 13, 2020 | clinicaltrials |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | terminated | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | Nov 6, 2020 | clinicaltrials |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | terminated | Phase 1 / Phase 2 | 12 | Autolus LimitedINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT02215096 | Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 37 | GlaxoSmithKlineINDUSTRY | 2 | Oct 22, 2020 | clinicaltrials |
| NCT03101280 | A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer | completed | Phase 1 | 29 | Hoffmann-La RocheINDUSTRY | 4 | Oct 22, 2020 | clinicaltrials |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 173 | Tracon Pharmaceuticals Inc.INDUSTRY | 4 | Oct 19, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT01999972 | A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | completed | Phase 1 | 50 | PfizerINDUSTRY | 2 | Sep 24, 2020 | clinicaltrials |
| NCT01219699 | A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | completed | Phase 1 | 221 | Novartis PharmaceuticalsINDUSTRY | 5 | Sep 22, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | terminated | Phase 1 | 2 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 16, 2020 | clinicaltrials |
| NCT03961100 | A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers. | completed | Phase 1 | 31 | Genentech, Inc.INDUSTRY | 1 | Sep 7, 2020 | clinicaltrials |
| NCT02064387 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 | completed | Phase 1 | 79 | GlaxoSmithKlineINDUSTRY | 3 | Aug 11, 2020 | clinicaltrials |
| NCT02722954 | A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 29 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 11, 2020 | clinicaltrials |
| NCT01425008 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma | completed | Phase 1 | 149 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 10, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT02211014 | An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma | completed | Phase 1 | 27 | Acerta Pharma BVINDUSTRY | 2 | Jul 31, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)(LTI) | unknown | Phase 1 / Phase 2 | 288 | St. Anna KinderkrebsforschungOTHER | 7 | Jul 14, 2020 | clinicaltrials |
| NCT01211262 | Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | completed | Phase 1 | 84 | Immunocore LtdINDUSTRY | 2 | Jul 8, 2020 | clinicaltrials |
| NCT03929172 | A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects | completed | Phase 1 | 20 | 2A Pharma ABINDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02812875 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | completed | Phase 1 | 71 | Curis, Inc.INDUSTRY | 4 | Jun 26, 2020 | clinicaltrials |
| NCT03138083 | OMO-1 in Solid Malignancies | terminated | Phase 1 / Phase 2 | 40 | Octimet Oncology N.V.INDUSTRY | 5 | Jun 11, 2020 | clinicaltrials |
| NCT01742286 | Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) | completed | Phase 1 | 83 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 9, 2020 | clinicaltrials |
| NCT01884285 | AZD8186 First Time In Patient Ascending Dose Study | completed | Phase 1 | 147 | AstraZenecaINDUSTRY | 4 | May 29, 2020 | clinicaltrials |
| NCT02261714 | Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer | completed | Phase 1 / Phase 2 | 32 | Targovax ASAINDUSTRY | 3 | May 14, 2020 | clinicaltrials |
| NCT02603419 | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) | terminated | Phase 1 | 34 | PfizerINDUSTRY | 3 | Apr 24, 2020 | clinicaltrials |
| NCT02013219 | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 6 | Apr 21, 2020 | clinicaltrials |
| NCT03002376 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) | completed | Phase 1 | 47 | Regeneron PharmaceuticalsINDUSTRY | 4 | Apr 20, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT02157792 | M6620 First in Human Study | completed | Phase 1 | 200 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | Apr 1, 2020 | clinicaltrials |
| NCT03198130 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) | completed | Phase 1 | 33 | Regeneron PharmaceuticalsINDUSTRY | 2 | Mar 19, 2020 | clinicaltrials |
| NCT01587703 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | completed | Phase 1 | 196 | GlaxoSmithKlineINDUSTRY | 7 | Mar 16, 2020 | clinicaltrials |
| NCT01970540 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | completed | Phase 1 | 122 | PharmaMarINDUSTRY | 2 | Mar 9, 2020 | clinicaltrials |
| NCT02401542 | Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-21) | terminated | Phase 1 / Phase 2 | 71 | Rainier TherapeuticsINDUSTRY | 9 | Mar 9, 2020 | clinicaltrials |
| NCT02261220 | A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 380 | MedImmune LLCINDUSTRY | 9 | Mar 6, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials